Itulazax (Betula Verrucosa (108))

Betula verrucosa extract contains purified birch pollen proteins. Repeated sublingual exposure modulates the immune system, shifting the response from an IgE‑driven allergic pathway toward a regulatory T‑cell and IgG4‑dominant profile. This reduces hypersensitivity and alleviates clinical symptoms over time.

The dosing regimen for Itulazax is individualized and determined by the prescribing healthcare professional. The prescriber selects the initial dose, escalation schedule, and maintenance level based on the patient’s sensitivity, age, and clinical response.

Safety data for Itulazax in pregnancy and lactation are limited. Because the risk cannot be fully assessed, it should only be used if the potential benefit justifies the potential risk to the fetus or infant, and only under medical supervision.

To order Itulazax, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Itulazax delivers the birch pollen allergen via a sublingual route, which is non‑invasive compared with subcutaneous injections. This method often results in fewer systemic reactions and allows self‑administration at home, while still achieving comparable long‑term tolerance when used according to a prescribed schedule.

Itulazax should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations. Do not refrigerate unless specifically instructed by the manufacturer.

Itulazax is administered sublingually. The patient places the prescribed dose under the tongue, holds it for the recommended time (usually 1–2 minutes), and then swallows. Administration should be performed on an empty stomach, and patients should avoid eating or drinking for a short period afterward as advised by their clinician.

The most serious risks include systemic allergic reactions such as anaphylaxis, angioedema, and severe bronchospasm. Patients should be educated to recognize early signs of systemic involvement and seek immediate medical attention if symptoms such as difficulty breathing, swelling of the face or throat, or rapid onset of hives occur.

Itulazax is contraindicated in individuals with a history of severe systemic reactions to birch pollen extracts, uncontrolled asthma, or those receiving beta‑blocker therapy that could mask anaphylaxis. It should also be avoided in patients with known hypersensitivity to any component of the formulation.